Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last ¥6,082 JPY
Change Today +14.00 / 0.23%
Volume 958.7K
4502 On Other Exchanges
Symbol
Exchange
Tokyo
OTC US
OTC US
Frankfurt
As of 2:00 AM 07/29/15 All times are local (Market data is delayed by at least 15 minutes).

takeda pharmaceutical co ltd (4502) Snapshot

Open
¥6,105
Previous Close
¥6,068
Day High
¥6,117
Day Low
¥6,057
52 Week High
03/6/15 - ¥6,657
52 Week Low
10/17/14 - ¥4,338
Market Cap
4.8T
Average Volume 10 Days
1.9M
EPS TTM
¥-185.58
Shares Outstanding
790.0M
EX-Date
09/28/15
P/E TM
--
Dividend
¥180.00
Dividend Yield
2.96%
Current Stock Chart for TAKEDA PHARMACEUTICAL CO LTD (4502)

Related News

No related news articles were found.

takeda pharmaceutical co ltd (4502) Details

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, sale, and import/export of pharmaceutical drugs worldwide. It provides products in various therapeutic areas, including cardiovascular and metabolic, respiratory and immunology, oncology, central nervous system, general medicine, vaccines, and consumer healthcare drugs and quasi-drugs. The company has strategic partnership with BioMotiv, LLC; and a collaboration agreement with Mersana Therapeutics Inc. and Queen Mary University of London. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Osaka, Japan.

31,328 Employees
Last Reported Date: 06/26/15
Founded in 1781

takeda pharmaceutical co ltd (4502) Top Compensated Officers

Chief Executive Officer, President and Repres...
Total Annual Compensation: ¥230.0M
Senior Managing Director, Corporate Strategy ...
Total Annual Compensation: ¥85.0M
Compensation as of Fiscal Year 2015.

takeda pharmaceutical co ltd (4502) Key Developments

Takeda Pharmaceutical Co. Consolidate its U.S. Vaccine Operations in Boston/Cambridge Area; Closes Facilities in Madison, Fort Collins, Bozeman and Deerfield, Illinois

Takeda Pharmaceutical Co. announced that it is consolidating its U.S. vaccine operations in the Boston/Cambridge area. The company closing facilities in Madison; Fort Collins, Colorado; Bozeman, Montana; and Deerfield, Illinois.

Takeda Pharmaceutical Company Limited Submits New Drug Application for ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

Takeda Pharmaceutical Company Limited announced that a new drug application (NDA) has been submitted to the United States (U.S.) Food and Drug Administration (FDA) for ixazomib, an investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma. The NDA submission was based on the pivotal Phase 3 trial TOURMALINE-MM1, an international, randomized, double-blind, placebo controlled clinical trial of 722 patients designed to evaluate the superiority of ixazomib plus lenalidomide and dexamethasone over placebo plus lenalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma. Patients continue to be treated in this trial and evaluated for long-term outcomes.

Takeda Pharmaceutical Company Limited Announces Executive Appointments

Takeda Pharmaceutical Company Limited announced the appointment of Yasuchika Hasegawa as Director, Chairman of the Board from his previous position Representative Director, Chairman of the Board. The company also appointed Andrew Plump, M.D., Ph.D. as Director, Chief Medical and Scientific Officer from his previous position Corporate Officer and Yasuhiko Yamanaka as Corporate Auditor from his previous position Managing Director.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4502:JP ¥6,082.00 JPY +14.00

4502 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $50.94 USD +0.25
Baxter International Inc $38.09 USD +0.39
Becton Dickinson and Co $149.88 USD +3.55
Biogen Inc $319.93 USD +10.50
Merck KGaA €93.35 EUR +0.83
View Industry Companies
 

Industry Analysis

4502

Industry Average

Valuation 4502 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.6x
Price/Book 2.2x
Price/Cash Flow 153.6x
TEV/Sales 1.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact TAKEDA PHARMACEUTICAL CO LTD, please visit www.takeda.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.